(Total Views: 2245)
Posted On: 01/22/2021 5:49:10 PM
Post# of 87011
Oh this is big.....
Who is on the board of directors for biopark at unviserity of Maryland?
https://www.umbiopark.com/biopark/park-leadership
DR DAVID DALTON
https://www.umaryland.edu/news/archived-news/...ired-f.php
https://www.catalent.com/catalent-news/catale...candidate/
https://www.fiercepharma.com/manufacturing/j-...n-facility
Who is on the board of directors for biopark at unviserity of Maryland?
https://www.umbiopark.com/biopark/park-leadership
DR DAVID DALTON
Quote:
Paragon Bioservices, Inc., the University of Maryland BioPark’s largest tenant and one of its fastest-growing biotechnology companies, is celebrating another success with the announcement that it has entered into a definitive agreement under which Catalent, Inc., a New Jersey-based contract drug manufacturer, will acquire Paragon for $1.2 billion.
https://www.umaryland.edu/news/archived-news/...ired-f.php
Quote:
Somerset, N.J., April 29, 2020 – Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability of manufacturing capacity and prepare for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnson’s lead vaccine candidate for COVID-19.
https://www.catalent.com/catalent-news/catale...candidate/
Quote:
Johnson & Johnson has been on a manufacturing deal spree as it nears human trials for its COVID-19 vaccine hopeful. On the same day it inked a $480 million order from a Maryland CDMO, J&J announced it would expand its pact with another manufacturer to scale up production as fast as possible.
J&J has expanded its COVID-19 vaccine manufacturing pact with New Jersey-based Catalent to include work at the CDMO's Anagni, Italy, facility, a J&J spokesman said Monday.
New Jersey-based J&J initially tapped Catalent in April to reserve fill-finish capacity for its COVID-19 shot at its Bloomington, Indiana, plant. As part of that deal, Catalent agreed to hire an additional 300 workers at the plant starting this month, with the goal of reaching 24/7 manufacturing schedules by January.
https://www.fiercepharma.com/manufacturing/j-...n-facility
(17)
(0)
